Video
Dr. Siddiqi on the Results of the TRANSCEND CLL 004 Trial in CLL
Author(s):
In Partnership With:
Tanya Siddiqi, MD, discusses the results of the TRANSCEND CLL 004 trial.
Tanya Siddiqi, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the results of the TRANSCEND CLL 004 trial.
The TRANSCEND CLL 004 study treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with lisocabtagene maraleucel (liso-cel). The trial showed that the CAR T-cell therapy was well tolerated. One patient experienced grade 3 cytokine release syndrome (CRS), which was manageable/reversible and 3 patients experienced grade 3 neurological events.
The outcomes of the study were encouraging. At the first assessment, the overall response rate was 81.5% and the complete remission rate was 45.5%. Undetectable minimal residual disease testing was found in 65% in the marrow as well.
